Down 18% on Oct 23, and still 25% under its Oct 22 close.
“Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA.”
−3Long-term trend
PHAT's Quality Score rose 2 points on Fri, Nov 6, to -4. It closed near its high of the day (2 chart checks started).
Follow PHAT's trial news. Pro members can get an alert when Phathom Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | Moves 10.1% a day with no profit behind it |
| Latest filing | 8-K, Oct 29 |
Mon Nov 9: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
3 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed -4.6% on average, higher 1 of 4 times.
About 19 quarters
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
PHAT is #203 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 203 |
Expected to report Thu Feb 25, before the open (in 108 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase was due to continued growth from execution of Phathom’s commercial strategy.”
PHAT's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase was primarily due to higher promotional and personnel-related expenses.”
From its results filing (SEC filing · Oct 29)
Its share count grew 23% a year over 3 years.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 29, 2026 | +11.5% | -1.0% | -9.6% |
| Jul 30, 2026 | -23.5% | -22.4% | -29.3% |
| Apr 30, 2026 | -2.7% | -4.9% | +7.6% |
Sales grew every year from 2022 to 2025, to $175M. It lost money in each of the four years.
RSI 31.8, MACD below signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: PHAT is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
“The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and strong emphasis on proprietary products.”
PHAT scores -4 today, which Breakaway calls Poor. It is #203 of 281 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 18% on Oct 23, and still 25% under its Oct 22 close. Cash lasts about 19 quarters at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
PHAT scores -4 today, which Breakaway calls Poor (below zero). That is #203 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PHAT's -4.
Expected to report Thu Feb 25, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. PHAT closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free for 24 hours. No account. No card. Then keep going with a free account.